Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532463 | 1.00 | PARP1 (0.59) | PARP1TSHRPOLBCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL26628569 | 0.98 | PARP1 (0.57) | PARP1TSHRPOLBCYP3A4MAPT | |
| Ammonia Solution, Strong SCHEMBL29199663 | 0.98 | PARP1 (0.57) | PARP1TSHRPOLBCYP3A4MAPT | |
| SCHEMBL36694 | 0.83 | PARP1 (0.73) | PARP1TSHRPOLBCYP3A4MAPT | |
| SCHEMBL31021028 | 0.83 | PARP1 (0.73) | PARP1TSHRPOLBCYP3A4MAPT | |
| SCHEMBL2093436 | 0.82 | HDAC1 (0.44) | PARP1TDP1L3MBTL1MTORHDAC1 | |
| SCHEMBL18079795 | 0.81 | CES2 (0.54) | MTORHDAC1HDAC2GRM5F2 | |
| SCHEMBL3673834 | 0.81 | ATM (0.58) | TDP1L3MBTL1MTORHDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL1367509 | 0.80 | PARP1 (0.70) | PARP1TSHRPOLBCYP3A4MAPT | |
| Water SCHEMBL7768285 | 0.80 | PARP1 (0.70) | PARP1TSHRPOLBCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110642741-A | Functionalized benzamide derivatives as antiviral agents against HBV infection | 巴鲁克斯布隆伯格研究所 | 2020-01-03 | — | — | CN | claimed |
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2015-10-29 | — | — | US | claimed |
| EP-2928459-A2 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Baruch S. Blumberg Institute (US) | 2015-10-14 | — | — | EP | claimed |
| WO-2014089296-A2 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2014-06-12 | — | — | WO | claimed |
| US-7968748-B2 | Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest | ABIOGEN PHARMA S.P.A. (IT) | 2011-06-28 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | claimed |
| EP-1986996-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | Abiogen Pharma S.p.A. (IT) | 2008-11-05 | — | — | EP | claimed |
| WO-2007088571-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2007-08-09 | — | — | WO | claimed |
| CN-122094719-A | System with improved hydrogel formation time | — | 2026-05-26 | — | — | CN | disclosed |
| US-12552739-B2 | Method for preparing primary amide compounds from secondary or tertiary amides | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2026-02-17 | — | — | US | disclosed |
| US-20250128220-A1 | SYSTEMS WITH IMPROVED HYDROGEL FORMATION TIMES | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119185628-A | Self-developing liquid-carried medicine embolic agent and preparation method and application thereof | 科睿驰（深圳）医疗科技发展有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240358867-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-10-31 | — | — | US | disclosed |
| WO-1996016046-A2 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-05-30 | — | — | WO | disclosed |
| EP-0648130-A1 | RADIOIODINATED BENZOVESAMICOL ANALOGS FOR CHOLINERGIC NERVE MAPPING | THE UNIVERSITY OF MICHIGAN (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0648130-A4 | RADIOIODINATED BENZOVESAMICOL ANALOGS FOR CHOLINERGIC NERVE MAPPING. | UNIV MICHIGAN (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1991017776-A1 | RADIOIODINATED BENZOVESAMICOL ANALOGS FOR CHOLINERGIC NERVE MAPPING | THE UNIVERSITY OF MICHIGAN (US) | 1991-11-28 | — | — | WO | disclosed |
| US-4327178-A | Urinary kallikrein assay: specific substrates and assay method | UNIVERSITY OF MIAMI (US) | 1982-04-27 | — | — | US | disclosed |
| US-3943152-A | Method for preparing azines | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358867-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | CDC73, MYCBP, TP53 | PARP1 3459/4885TSHR 1649/4885POLB 633/4885 |
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, PHB2, PHB1 | PARP1 666/4885TSHR 3362/4885POLB 232/4885 |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | SRR, EPHX2, ALOX5 | PARP1 2055/4885TSHR 4205/4885POLB 1541/4885 |
| US-12552739-B2 | Method for preparing primary amide compounds from secondary or tertiary amides | CPS1, NAAA, MLN | PARP1 1342/4885TSHR 1408/4885POLB 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.